【摘要】 目的　探索ELFP方案治疗转移复发的晚期鼻咽癌、食管癌、胃癌的临床疗效和毒性。方法　选择病理证实的 6 4例晚期鼻咽癌、食管癌、胃癌采用Vp - 16 0 .1g静滴 ,d1～ 3 ;CF 0 .1g静滴 ,d1～ 3 5 -FU 0 .5g静滴 ,d1～ 3 ;DDP 5 0mg静滴 ,d1～ 2 ;2 1d为 1周期。治疗 2～ 6个周期。结果　鼻咽癌 ,食管癌、胃癌有效率 (CR +PR)分别为 75 %、70 %、4 3.8% ,其中胃癌与鼻咽癌及食管癌分别比较有差异 ;单病灶与多病灶之间疗效无差异。全组病例总生存期为 3～ 4 1月 ,中位生存期分别为 11.5、10、7.5个月。主要毒性为骨髓抑制 ,其中Ⅲ、Ⅳ度白细胞下降占 2 1.9% ;Ⅲ、Ⅳ度血红蛋白下降占 15 .6 % ;Ⅲ、Ⅳ度血小板下降占 3.1%。Ⅲ、Ⅳ度恶心、呕吐发生率为 7.8%。结论　ELFP对晚期鼻咽癌及食管癌有较好的疗效 ,其毒性可以耐受 ,是临床治疗鼻咽癌 ,食管癌切实可行的方案。更多还原

【Abstract】 Objective: To evaluate the clinical effects and toxicities of ELFP regimen in advanced nas opharyngeal carcinoma (NPC) and upper digestive cancer.Methods: 64 patients of NPC,esophagus carcinoma and gastric cancer proved by pathology w ere collected in this trial. All patients were treated for 2 ～6 cycles with ELF P regimen in which there were Vp-16 0.1g iv drip d 1～3 ,CF 0.1 g iv drip d 1～3 and 5-Fu 0.5 g iv drip d 1～3 ,DDP 50 mg iv drip d 1～2 ,r epeated every 21 days. Results: The response rates (CP+PR) in NP C,esophageal carcinoma and gastric cancer were 75%,70% and 43.8%,respectively . The survival time was 3～41 months in all of 3 groups,median survival time wa s 11.5,10 and 7.5 months in NPC,esophageal carcinoma and gastric cancer,respec tively. Toxicity included mainly bone marrow suppression,21.9% of grade Ⅲ and Ⅳ neutropenia,15.6% of grade Ⅲ and Ⅳ hemoglobin decrease and 7.8% of grade Ⅲ and Ⅳ thrombocytopenia,as well as 7.8% of grade Ⅲ and Ⅳ of nausea and v omiting. Conclusion: ELFP is an effective and practicable regime n for advanced NPC esophagus carcinoma with tolerable toxicities.更多还原